Validea Kenneth Fisher Strategy Daily Upgrade Report

Validea's Price/Sales Investor model, based on the Kenneth Fisher strategy, upgraded its rating for Omnicell Inc (OMCL) from 50% to 70%, AngioDynamics, Inc. (ANGO) from 48% to 60%, and OPKO Health Inc (OPK) from 48% to 60% based on underlying fundamentals and valuation; while all three companies passed tests for Price/Sales Ratio, Total Debt/Equity Ratio, and Price/Research Ratio, they failed tests for Price/Sales Ratio, Long-Term EPS Growth Rate, and Three Year Average Net Profit Margin, with ANGO and OPK also failing the Free Cash Per Share test, indicating mixed interest from the value strategy.

Analysis

Validea's Kenneth Fisher model has upgraded Omnicell Inc. (OMCL) to a 70% rating, and both AngioDynamics, Inc. (ANGO) and OPKO Health Inc. (OPK) to 60%, citing re-evaluated underlying fundamentals and stock valuations. These scores, while representing an improvement, remain below the 80% threshold that typically indicates significant interest from this specific value strategy. All three small-cap growth companies successfully passed tests for Total Debt/Equity Ratio and Price/Research Ratio, and notably, also passed one Price/Sales Ratio criterion, suggesting some alignment with the strategy's preference for low P/S multiples. However, a point of concern is that all three also failed a separate Price/Sales Ratio test. More critically, OMCL, ANGO, and OPK all failed to meet the strategy's requirements for Long-Term EPS Growth Rate and Three-Year Average Net Profit Margin, which are core tenets of Fisher's approach focused on long-term profit growth and consistent margins. Further differentiation is evident in cash flow metrics: OMCL passed its Free Cash Per Share test, a positive signal, whereas ANGO and OPK both failed this criterion, indicating potentially weaker cash generation profiles. The upgrades therefore reflect a nuanced, mildly positive sentiment, but the persistent failures on key profitability and growth metrics suggest these companies do not yet fully meet the ideal characteristics sought by the Kenneth Fisher model.

Key Decisions for Investors

• Investors should acknowledge the upward revisions in Validea's Fisher model scores for OMCL, ANGO, and OPK, but exercise caution as these ratings are still shy of the 80% 'interest' threshold and do not indicate strong conviction from the model.
• The mixed screening results, particularly passing one Price/Sales Ratio test and debt/equity metrics while failing another P/S test alongside crucial long-term EPS growth and average net profit margin criteria, necessitate in-depth due diligence into the underlying drivers of these conflicting signals.
• Particular attention should be paid to the fundamental reasons behind the lack of long-term EPS growth and subpar profit margins for all three firms; for ANGO and OPK, the additional failure on free cash flow per share presents another significant area for scrutiny before considering investment based on this specific value strategy.